Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632 1648 1671 1672
This examiner grants 68% of resolved cases
M Franco G Salvoza has resolved 623 cases in Tech Center 1600. The examiner has an allowance rate of 68.5 percent. This rate suggests a fair chance of success in Art Unit 1600. The 68.5 percent allowance rate indicates that the examiner is generally open to granting patents when the applications meet the necessary requirements.
The interview lift is 29.8 percent. This high lift indicates that interviews are very effective at resolving issues and securing allowances. A 29.8 percent increase in the probability of success following an interview makes direct communication a highly recommended tactic for practitioners working with this examiner.
The median days to allowance is 1155. This timeframe represents the typical path to grant for successful cases. Practitioners should use the 1155 day median to set expectations for the length of the grant process while leveraging the 29.8 percent interview lift to improve their overall chances of success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17775206 | CRISPR COMPLEX-BASED DETECTION SYSTEM AND METHOD | Non-Final OA | University of Florida Research Foundation, Inc. |
| 19217607 | VECTOR-BASED GENE THERAPY FOR ELONGATOR ACETYLTRANSFERASE COMPLEX SUBUNIT 1 (ELP1) | Non-Final OA | University of Massachusetts |
| 18779855 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Non-Final OA | DYNO THERAPEUTICS, INC. |
| 18761730 | CAPSID VARIANTS AND METHODS OF USING THE SAME | Non-Final OA | DYNO THERAPEUTICS, INC. |
| 18044568 | NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Final Rejection | Merck Patent GmbH |
| 18757357 | GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18027067 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | Non-Final OA | The Johns Hopkins University |
| 17925179 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING A SARS-COV-2 INFECTION | Non-Final OA | EMORY UNIVERSITY |
| 17671467 | NOVEL IMMUNOASSAY FORMAT FOR MEASURING TOTAL ANTIBODIES | Final Rejection | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. |
| 17187678 | RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS | Non-Final OA | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA |
| 18000772 | MODIFIED ALPHAVIRUS FOR USE AS COVID-19 VACCINE | Non-Final OA | New York University |
| 18210829 | LIVE ATTENUATED ZIKA VIRUS WITH 3'UTR DELETION, VACCINE CONTAINING AND USE THEREOF | Final Rejection | Board of Regents, The University of Texas System |
| 18643377 | RABIES VIRUS VACCINE | Non-Final OA | Intervet Inc. |
| 18034312 | TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17999071 | Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins | Non-Final OA | National Research Council of Canada |
| 17917058 | ASSAY TO DETECT VIRUS | Non-Final OA | CORNELL UNIVERSITY |
| 17293861 | VECTORS COMPRISING A NUCLEIC ACID ENCODING LYSOSOMAL ENZYMES FUSED TO A LYSOSOMAL TARGETING SEQUENCE | Non-Final OA | ASKBIO INC. |
| 18615749 | PRE-IMMUNIZATION AND IMMUNOTHERAPY | Non-Final OA | American Gene Technologies International Inc. |
| 17918184 | METHOD FOR DETERMINING THE RISK OF INCIDENCE OF A CARE-ASSOCIATED INFECTION IN A PATIENT | Non-Final OA | HOSPICES CIVILS DE LYON |
| 18564263 | COMBINED AGONIST ADJUVANT FOR CORONAVIRUS VACCINE | Non-Final OA | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | Final Rejection | Greffex, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy